Trials / Approved For Marketing
Approved For MarketingNCT02141087
Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone |
Timeline
- First posted
- 2014-05-19
- Last updated
- 2015-07-13
Source: ClinicalTrials.gov record NCT02141087. Inclusion in this directory is not an endorsement.